ATE396745T1 - Complex enthaltend modafinil und cyclodextrin - Google Patents
Complex enthaltend modafinil und cyclodextrinInfo
- Publication number
- ATE396745T1 ATE396745T1 AT01994302T AT01994302T ATE396745T1 AT E396745 T1 ATE396745 T1 AT E396745T1 AT 01994302 T AT01994302 T AT 01994302T AT 01994302 T AT01994302 T AT 01994302T AT E396745 T1 ATE396745 T1 AT E396745T1
- Authority
- AT
- Austria
- Prior art keywords
- cyclodextrin
- complex containing
- containing modafinil
- modafinil
- modafinil compound
- Prior art date
Links
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 3
- 229960001165 modafinil Drugs 0.000 title abstract 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 3
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- -1 modafinil compound Chemical class 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25668100P | 2000-12-19 | 2000-12-19 | |
| US10/023,441 US7141555B2 (en) | 2000-12-19 | 2001-12-18 | Modafinil compound and cyclodextrin mixtures |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE396745T1 true ATE396745T1 (de) | 2008-06-15 |
Family
ID=26697157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01994302T ATE396745T1 (de) | 2000-12-19 | 2001-12-19 | Complex enthaltend modafinil und cyclodextrin |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7141555B2 (de) |
| EP (1) | EP1368063B1 (de) |
| JP (1) | JP4094428B2 (de) |
| KR (1) | KR20040012696A (de) |
| CN (1) | CN100384477C (de) |
| AT (1) | ATE396745T1 (de) |
| AU (1) | AU2002246711B2 (de) |
| BG (1) | BG108009A (de) |
| BR (1) | BR0116698A (de) |
| CA (1) | CA2432126C (de) |
| CZ (1) | CZ20031878A3 (de) |
| DE (1) | DE60134274D1 (de) |
| EA (1) | EA200300705A1 (de) |
| ES (1) | ES2305128T3 (de) |
| HU (1) | HUP0401592A2 (de) |
| IL (1) | IL156470A0 (de) |
| MX (1) | MXPA03005505A (de) |
| NO (1) | NO20032788L (de) |
| NZ (1) | NZ526780A (de) |
| PL (1) | PL362474A1 (de) |
| SK (1) | SK9012003A3 (de) |
| WO (1) | WO2002056915A2 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003074474A2 (en) | 2002-03-01 | 2003-09-12 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
| US20040116532A1 (en) | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
| JP2004250390A (ja) * | 2003-02-21 | 2004-09-09 | Taisho Pharmaceut Co Ltd | 鉄化合物配合内服液剤 |
| HRP20050925A2 (en) * | 2003-03-28 | 2006-08-31 | Ivax Corporation | Oral formulations of cladribine |
| ES2584183T3 (es) * | 2003-03-28 | 2016-09-26 | Ares Trading S.A. | Formulaciones de cladribina para suministro mejorado oral y transmucosa |
| CN1874993B (zh) * | 2003-09-04 | 2010-12-08 | 赛福伦公司 | 莫达芬尼组合物 |
| AU2004270238B2 (en) * | 2003-09-04 | 2010-07-29 | Cephalon, Inc. | Modafinil compositions |
| US7566805B2 (en) | 2003-09-04 | 2009-07-28 | Cephalon, Inc. | Modafinil compositions |
| AR046410A1 (es) | 2003-09-18 | 2005-12-07 | Cephalon Inc | Composiciones farmaceuticas para la liberacion modificada de modafinilo |
| US20090018202A1 (en) | 2004-02-06 | 2009-01-15 | Cephalon, Inc. | Modafinil compositions |
| US20050250738A1 (en) * | 2004-05-06 | 2005-11-10 | Mosher Gerold L | Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin |
| US20060024370A1 (en) * | 2004-07-29 | 2006-02-02 | Cephalon France | Modafinil oral lyophilizate |
| CN100503647C (zh) * | 2005-11-02 | 2009-06-24 | 南京师范大学 | 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用 |
| MX2009000391A (es) * | 2006-07-12 | 2009-06-30 | Elan Pharma Int Ltd | Formulación de modafinilo en forma de nano-partículas. |
| JP2009091309A (ja) * | 2007-10-10 | 2009-04-30 | Japan Organo Co Ltd | バコパモニエラエキスを含有する組成物およびその製造方法ならびに飲食品 |
| US10463677B2 (en) | 2008-11-07 | 2019-11-05 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
| KR101026864B1 (ko) * | 2009-10-08 | 2011-04-12 | (주)송호바이오메드 | 고 수용성 ２―하이드록시프로필―베타사이클로덱스트린을 유효성분으로 함유하는 비만 질환 예방 및 치료용 조성물 |
| WO2011043630A2 (ko) * | 2009-10-08 | 2011-04-14 | (주)송호바이오메드 | 고 수용성 ２-하이드록시프로필-베타사이클로덱스트린을 유효성분으로 함유하는 비만 질환 예방 및 치료용 조성물 |
| PH12013500477A1 (en) | 2010-09-13 | 2018-01-17 | Bev Rx Inc | Aqueous drug delivery system comprising off-flavor masking agent |
| US9474715B2 (en) | 2011-11-30 | 2016-10-25 | Andreas Voigt | Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition |
| US9364549B2 (en) | 2011-11-30 | 2016-06-14 | Andreas Voigt | Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition |
| US9616068B2 (en) | 2014-10-27 | 2017-04-11 | Pohela LLC | Animal training using cognitive enhancement |
| KR101719987B1 (ko) | 2015-08-03 | 2017-03-27 | (주)상전정공 | 화물차량의 잠금장치 |
| US9855228B1 (en) * | 2016-12-14 | 2018-01-02 | Taho Pharmaceuticals Ltd. | Oral solution comprising atomoxetine hydrochloride and methods thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5835968B2 (ja) * | 1974-02-25 | 1983-08-05 | 帝人株式会社 | サイクロデキストリン包接化合物の製造法 |
| GB1584462A (en) | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
| JPS5920230A (ja) | 1982-07-19 | 1984-02-01 | チバ−ガイギ−・アクチエンゲゼルシヤフト | ピルプロフエン含有薬剤 |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| FR2593809B1 (fr) * | 1986-01-31 | 1988-07-22 | Lafon Labor | Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique |
| JPS62281855A (ja) * | 1986-05-29 | 1987-12-07 | Daikin Ind Ltd | ビタミン，ビタミン誘導体，またはホルモンを含有する包接化合物 |
| GB8813682D0 (en) * | 1988-06-09 | 1988-07-13 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions |
| JPH035438A (ja) * | 1989-05-31 | 1991-01-11 | Kaken Pharmaceut Co Ltd | フルルビプロフェン包接化合物およびこの包接化合物を用いる消炎鎮痛剤 |
| SE8902235D0 (sv) * | 1989-06-20 | 1989-06-20 | Haessle Ab | Novel cyclodextrin inclusion complexes |
| FR2663225B1 (fr) | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
| US5024997A (en) | 1990-06-22 | 1991-06-18 | American Home Products Corporation | Palatable ibuprofen solutions |
| FR2684875B1 (fr) * | 1991-12-13 | 1995-05-24 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique. |
| US5843347A (en) | 1993-03-23 | 1998-12-01 | Laboratoire L. Lafon | Extrusion and freeze-drying method for preparing particles containing an active ingredient |
| FR2702968B1 (fr) | 1993-03-23 | 1995-06-23 | Lafon Labor | Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation . |
| US5866162A (en) | 1993-08-10 | 1999-02-02 | Smithkline Beecham P.L.C. | Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple |
| US5618845A (en) | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
| US6077871A (en) | 1997-11-26 | 2000-06-20 | Pfizer Inc. | Droloxifene pharmaceutical compositions |
| US6200968B1 (en) | 1998-08-06 | 2001-03-13 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
| US6346548B1 (en) * | 1999-08-16 | 2002-02-12 | Cephalon, Inc. | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| US6455588B1 (en) * | 1999-08-20 | 2002-09-24 | Cephalon, Inc. | Compositions including modafinil for treatment of eating disorders and for appetite stimulation |
-
2001
- 2001-12-18 US US10/023,441 patent/US7141555B2/en not_active Expired - Fee Related
- 2001-12-19 EA EA200300705A patent/EA200300705A1/ru unknown
- 2001-12-19 ES ES01994302T patent/ES2305128T3/es not_active Expired - Lifetime
- 2001-12-19 PL PL01362474A patent/PL362474A1/xx unknown
- 2001-12-19 CA CA2432126A patent/CA2432126C/en not_active Expired - Fee Related
- 2001-12-19 MX MXPA03005505A patent/MXPA03005505A/es active IP Right Grant
- 2001-12-19 IL IL15647001A patent/IL156470A0/xx unknown
- 2001-12-19 JP JP2002557422A patent/JP4094428B2/ja not_active Expired - Fee Related
- 2001-12-19 WO PCT/US2001/049189 patent/WO2002056915A2/en not_active Ceased
- 2001-12-19 AU AU2002246711A patent/AU2002246711B2/en not_active Ceased
- 2001-12-19 AT AT01994302T patent/ATE396745T1/de not_active IP Right Cessation
- 2001-12-19 NZ NZ526780A patent/NZ526780A/en not_active IP Right Cessation
- 2001-12-19 CN CNB018207669A patent/CN100384477C/zh not_active Expired - Fee Related
- 2001-12-19 DE DE60134274T patent/DE60134274D1/de not_active Expired - Lifetime
- 2001-12-19 HU HU0401592A patent/HUP0401592A2/hu unknown
- 2001-12-19 SK SK901-2003A patent/SK9012003A3/sk unknown
- 2001-12-19 BR BR0116698-0A patent/BR0116698A/pt not_active IP Right Cessation
- 2001-12-19 KR KR10-2003-7008220A patent/KR20040012696A/ko not_active Withdrawn
- 2001-12-19 EP EP01994302A patent/EP1368063B1/de not_active Expired - Lifetime
- 2001-12-19 CZ CZ20031878A patent/CZ20031878A3/cs unknown
-
2003
- 2003-06-18 NO NO20032788A patent/NO20032788L/no not_active Application Discontinuation
- 2003-07-18 BG BG108009A patent/BG108009A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK9012003A3 (en) | 2003-12-02 |
| DE60134274D1 (en) | 2008-07-10 |
| NZ526780A (en) | 2005-07-29 |
| HK1059055A1 (en) | 2004-06-18 |
| CA2432126A1 (en) | 2002-07-25 |
| BR0116698A (pt) | 2003-10-21 |
| KR20040012696A (ko) | 2004-02-11 |
| EP1368063B1 (de) | 2008-05-28 |
| CN1486196A (zh) | 2004-03-31 |
| WO2002056915A3 (en) | 2003-01-03 |
| JP2004525104A (ja) | 2004-08-19 |
| NO20032788L (no) | 2003-07-07 |
| US20020160982A1 (en) | 2002-10-31 |
| HUP0401592A2 (hu) | 2004-11-29 |
| EA200300705A1 (ru) | 2003-12-25 |
| CA2432126C (en) | 2011-03-08 |
| CN100384477C (zh) | 2008-04-30 |
| EP1368063A2 (de) | 2003-12-10 |
| CZ20031878A3 (cs) | 2004-10-13 |
| NO20032788D0 (no) | 2003-06-18 |
| BG108009A (en) | 2004-09-30 |
| MXPA03005505A (es) | 2003-10-06 |
| JP4094428B2 (ja) | 2008-06-04 |
| ES2305128T3 (es) | 2008-11-01 |
| IL156470A0 (en) | 2004-01-04 |
| WO2002056915A2 (en) | 2002-07-25 |
| AU2002246711B2 (en) | 2006-12-14 |
| US7141555B2 (en) | 2006-11-28 |
| PL362474A1 (en) | 2004-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60134274D1 (en) | Complex enthaltend modafinil und cyclodextrin | |
| CY1110061T1 (el) | Συνθεσεις περιλαμβανοντας ενωσεις μοδαφινιλης | |
| ATE376996T1 (de) | Antibakterielle mittel | |
| NO20030929L (no) | Guanidinobenzamider som MC4-R agonister | |
| CY1112687T1 (el) | Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες | |
| NO20025450L (no) | Ny farmasöytisk sammensetning | |
| ATE264863T1 (de) | 28-epirapaloge | |
| DE60106954D1 (de) | Resorcin-derivate | |
| CY1110258T1 (el) | Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης | |
| BRPI0508700A (pt) | uso de sns-595, composição farmacêutica, e, pó liofilizado | |
| EP1311820A4 (de) | Erhöhte trenneffizienz über gesteuerte aggregation magnetischer nanopartikel | |
| NO20040702L (no) | Kombinerte preparater som inneholder 1,4-benzotiepin-1,1-dioksidderivater og andre aktive substanser og anvendelsen derav | |
| CY1106056T1 (el) | Παραγωγα 2-αμινο-2-αλκυλ-5-επτενοϊκου και επτυνοϊκου οξεος χρησιμα σαν αναστολεις συνθασης νιτρικου οξειδιου | |
| ATE478662T1 (de) | Arzneilösungen enthaltend modafinilverbindungen | |
| ATE325135T1 (de) | 2-alkylierte cyclodextrinderivate : umkehrungsmittel von medikament-induzierter neuromuskulärer blockierung | |
| NO20014752D0 (no) | Taksanpreparater med forbedret opplöselighet | |
| IS6679A (is) | Ný form (R)-N-[5-metýl-8-(4-metýlpíperasín-1-ýl)-1,2,3,4-tetrahýdró-2-naftýl]-4-morfólínóbensamíðs | |
| TR200402030T4 (tr) | İkame edilen I-aminobutan-3-ol-türevleri | |
| TR201910060T4 (tr) | SYN3 bileşimleri ve yöntemleri. | |
| NO20023697L (no) | Cykliske heksapeptidderivater | |
| DE60232018D1 (de) | 3-phenyl-2-arylalkylthiopropionsäure-derivate als selektive agonisten von ppar-alpha | |
| ATE391489T1 (de) | Haarbehandlungszusammensetzungen | |
| NO20021429D0 (no) | 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner | |
| DE50305183D1 (de) | Perlglänzende wässrige Zubereitungen | |
| DK1259535T3 (da) | Cykliske hexapeptidderivater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |